Stanley M. Bergman
Chairman and Chief Executive Officer at Henry Schein
Sorry, we had evidently the line disconnected, but let me continue. I think I don't know where we ended. I think on the Lorelei we ended. So the decline in patient traffic was primarily the result of appointment cancellations, staffing shortages and some office closures given the spread of COVID, although, we believe patient traffic has now returned to December 2021 levels. I think I covered that already, and I think it went through. The global trends are somewhat varied depending on the region of the world.
So lower sales of PPE products in the quarter were primarily as a result of lowest labs sales. The glove market has been quite volatile for about a year, maybe a little longer, not much longer at 15 months. We expect glove pricing will be increasing -- will be an increasing headwind on for a few quarters, so prices peaked in the second quarter of last year that's 2021. Nevertheless, if you exclude PPE products, North American consumable merchandise internal sales growth in local currencies was quite solid. Despite the softer start to the quarter, we gained momentum as the quarter progressed. This was supported by good growth in sales to new DSO accounts.
Our North American dental equipment business has a very had a very good quarter with strong sales in both traditional and digital category, particularly in digital restorative restoration equipment. Our equipment order book in North America remained strong at the quarter end consistent with the backlog at the beginning of the quarter. So new orders continue to come in at a very nice rate. As commented earlier in the call, we did not see a significant impact from inflation on this quarter's equipment sales due to long lead times for equipment as we had largely locked in supplier prices for orders shipped during the quarter.
Our equipment results benefited from sales to some of our large DSOs as we believe that anticipation of further price increases. Also, we believe that anticipation of further price increases is modestly providing some of the elevated demand we see today, it's not a huge impact of -- as some orders coming in from customers who expect pricing to go up and would like to get in the date before the prices go up and not a huge impact. But I nevertheless point that out to you. We continue to experience supply chain issues for traditional equipment arising from component part shortage delays in office build-outs and renovation as well as longer lead times for digital imaging technology.
This is not that the product is not available it's just taking a little longer from the digital stride to deliver our orders. Having said that, if a practitioner needs anything urgently we of course, we'll make sure that we supply both traditional equipment and digital imaging. We now expect these equipment delays will continue to be factored through the second half of the year and will provide further support for good and will provide further support for good equipment sales over the next few quarters. In fact, bottom line is we remain bullish on the equipment market and especially the digital dental equipment product offering and we expect to continue demonstrating good growth in the digital category, including intraoral scanners.
And now -- the last period of time, the impact of digital 3D printings we're starting to see that flow through as well, that demand to be of interest. We continue to look for innovative ways to add value to our customers and last month, we hosted THRIVELIVE in Las Vegas. This is a three-day dental educational conference that it replaces with successful Dentrix business with dentistry conference we have held in years prior to COVID. We designed this inaugural event to offer a learning path to every member of the dental office from the front office to the hygienist in a dentist themselves. So everyone from the staff, Adrina all the way to dentists, participating in this conference and the program which is designed for the various players in the office.
We were also able to select from over 50 CE credited courses led by more than 40 leading commissions with the strong educational focus on digital technology and practice management solutions that Henry Schein has quite a bit of competency in advising our customers. The customer feedback we received has been most positive and at events like THRIVE, at least from our point of view, position us to connect with our customers in deeper ways and positions our team to help drive greater productivity and provide better clinical care in their practices, educational type events like this provide great sales opportunities as well.
Turning now to the international Dentrix business. International equipment sales were also quite strong for the quarter. International consumable sales were impacted by similar trends as in North America, including lower PP&E and COVID-19 related product sales and by decline in patient visit, particularly during the first half of the quarter. That said, compared to North America, the impact of COVID-19 was more pronounced internationally, especially in Europe. So still a bit more in Europe. Patient traffic picked up at better paces as the quarter progressed and COVID-19 restrictions were relaxed in certain parts of Europe, and we expect these markets to continue to recover.
We also expect the Australian market to start to recover having reached a peak COVID-19 infection rate towards the end of the quarter. This should help recast of our consumer prices in Europe, Australia and our billion business were strong throughout the first quarter. Now I see China impact our business note, our growing Chinese business is still a relatively small part of our global dental business. These lockdowns also intensified during our fiscal second quarter, so that they had little impact in the first quarter. I remind you though is we have a nice growing business in China, but it's not material in the real concept in the relative size of Henry Schein relative to has global consolidated sales.
Returning to dental specialties and technology and value-added services. Sales of our dental specialty products were solid during the first quarter, specifically oral surgery, which consists of dental implants and broad regeneration products. In particular, sales of BioHorizons, implants grew by double digits this quarter, executing well in North America, where this business is primarily focused and with the market for restorations continues to be quite strong. Camlog and dentist brands in Europe, primarily in Germany, also had quite a good quarter -- first quarter for the implants and the bone regeneration products in Europe. We have also had success selling our ACE bone regeneration products into the large DSO market.
And this is really another very good example of the dental in our bone strategy, leveraging one side strategic priorities. Now, within our endodontic products offering and endo business is also quite solid. We recently launched our EdgePRO Laser which is actually often quite a successful launch, having been well received at last week's AEA meeting here in the United States. We do believe that EdgePRO Laser offers outstanding cleaning, debridement and Disinfection, coupled with greater value compared with competing products.
Meanwhile, our priority in the orthodontic business is our real clear aligner product line, -- in March, we completed the U.S. domestic launch of the Studio Pro 40 product that's the software. And we are now rolling out the software update globally. Software features advanced treatment planning and utilization tools. Obviously, I think investors are aware that the endodontic sales were not great in the first quarter because of practices not being a full capacity i.e. as a result of COVID.
So overall, our solid position in Dental Specialty products is built upon strong customer offering. And our commitment to meaningful ongoing investments in R&D, there are questions on that, happy to provide further color during the call. Turning to technology value-added service sales, they also increased by double-digits during the first quarter in both South America and International. We believe, Henry Schein One offers one of the broadest product offerings of dental practice management and related software and services and is the largest contributor to sales in the sector of technology and value-added services.
Growth within Henry Schein One continues to be driven primarily by a recovery in patient traffic to dental offices, which generates demand for our revenue cycle management solutions and also by cloud-based solutions, our cloud-based solutions that create flexibility, scalable services to drive practice efficiency and yes, patient engagement too. As another example of our commitment to expanding our technology product offering, have begun making our Jarvis Analytics software product available to private dental practices whereas previously, the Jarvis software was available primarily to DSOs.
Also within our value-added services business is our E-assist business, which provides the revenue cycle management solutions for insurance reimbursements. We are quite pleased with the integration and performance of this business, which we acquired last year. So now turning to our Medical business, where the global medical sales were excellent, as we achieve further penetration into existing customer accounts. Internal sales growth in local currency, if you exclude PPE and COVID-19-related products also continued to be strong.
The US patient traffic to physician offices and alternate care sites and that, in particular, in our case, the Ambulatory Surgical centers was up consistently to our quarter one versus the prior year. Sales of medical laboratory equipment were up double-digits, while demand for non-COVID point-of-care diagnostic test was also quite strong. Sales of PPE products declined by double-digits compared to the strong first quarter last year. As I mentioned earlier, we expect further pricing declines for gloves throughout the rest of the year, net prices to remain above pre-pandemic levels. Sales of COVID-19 tests were extremely strong during January, very strong and declined sharply towards the end of the quarter.
The future of these products is difficult to predict as we face the somewhat offsetting forces of new variants, spreading rapidly trading demand along with increased availability of Home cash on the other side and many of which are being paid for by the government in the US.
So that's a broad overview. Now, Ron will give you more specifics on the financial results for the first quarter. So Rob, here you go. Thank you, and welcome to your first call.